Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Disease Area Cancer, Cell & molecular biology

Adaptive Invaders

Metastasis is the most dangerous step in a cancer’s evolution, yet specific therapies intended to inhibit the process remain elusive. Scientists have long focused on inhibiting matrix metalloproteinases (MMPs) – a family of enzymes that are believed to aid cell migration by degrading the dense network of proteins – called the basement membrane – that surrounds human tissues. Now, a study reported in Developmental Cell suggests there may be far more to the story of metastasis than previously thought (1).

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

  1. LC Kelley et al., “Adaptive F-actin Polymerization and Localized ATP Production Drive Basement Membrane Invasion in the Absence of MMPs.” Dev Cell, 18, 31084-6. [Epub ahead of print] (2019) PMID: 30686527

About the Author

Jonathan James

As an assistant editor for The Translational Scientist, I can combine two of my passions; translational science research and science communication. Having thrown myself into various editing and other science communication gigs whilst at University I came to realise the importance of good quality content that delivers in an exciting and engaging way.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register